Trending News on Targeted Oncology, Week of October 9, 2020

October 9, 2020
Danielle Ternyila

Targeted Oncology reviews trending news online for the week of October 9, 2020, including updates in oncology and new information regarding COVID-19.

This week, the FDA granted an Orphan Drug designation in gastric/gastroesophageal junction adenocarcinoma to an investigational chimeric antigen receptor (CAR) T-cell therapy. The FDA also issued a draft guidance encouraging the inclusion of premenopausal women with breast cancer in clinical trials, in order to help researchers determine the efficacy of a hormonal drug or biological products for this population along with others.

Check out the latest conference coverage this weekend from the NCCN 2020 Virtual Congress: Hematologic Malignancies.

These updates and others were trending:

FDA Grants Breakthrough Therapy Designation to CD123-Directed Antibody-Drug Conjugate

The FDA has granted a Breakthrough Therapy designation to IMGN632 as treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasms.

Pro Talks Treatment for Peripheral T-Cell Lymphoma

During a Targeted Oncology Case Based Peer Perspective event, Barbara Pro, MD, discussed the case of a 60-year-old male patient with peripheral T-cell lymphoma.

In Light of Recently Approved Regimens, Sequencing Strategies Are Under Discussion in HCC

Laura Goff, MD, discussed the combination of atezolizumab plus bevacizumab in relation to its effect on the treatment paradigm of hepatocellular carcinoma during a presentation at the 17th Annual Meeting of the International Society of Gastrointestinal Oncology.

CodeBreak Update Shows Durable Antitumor Activity With Sotorasib In KRAS-Mutant NSCLC

Topline results from the phase 2 CodeBreaK 100 clinical trial were consistent with phase 1 data, withthe KRAS inhibitor sotorasib (AMG 510) having achieved a satisfactory objective response rate when administered as treatment of patients with KRAS G12C–mutant non–small cell lung cancer, who had failed a median of 2 prior lines of anti-cancer therapies.

Expert Recognizes Expansion of HCC Treatment Options During Liver Cancer Awareness Month

In an interview with Targeted Oncology, David J. Pinato, MD, PhD, reviewed how the treatment landscape of hepatocellular carcinoma has evolved over the years and the challenges that clinicians and researchers currently face in the field.

Exploring the Tazemetostat Approval in R/R Follicular Lymphoma

Lori A. Leslie, MD, discusses the approval of tazemetostat in the follicular lymphoma setting and the data that that led to its FDA approval.

Special Feature: COVID-19

COVID-19 Pandemic Delays Treatment for HCC, Says French Cancer Center Analysis

In patients with advanced hepatocellular carcinoma treated in 2020, there was an observed decrease in planned treatment as well as significant delays noted as a result of the COVID-19 pandemic, according to the results of a study of 6 academic referral centers.